Synapse Open Synapse
Biology

Vertex, ahead of FDA decision, calms fears surrounding kidney drug

BioPharma Dive · · 3 min read

On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.

Latest from BioPharma Dive